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| INTRODUC TI ON
Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of liver conditions, ranging from bland steatosis to nonalcoholic steatohepatitis (NASH), which results in progressive hepatic fibrosis.
Patients with NAFLD are at risk of liver cirrhosis and hepatocellular carcinoma. 1 The pathogenesis of NAFLD is still not entirely understood. The risk is increased by environmental risk factors such as metabolic-related challenges but also in the presence of genetic variations. 2 For instance, the mutation p.I148M in the gene encoding the triglyceride hydrolase patatin-like phospholipase domain-containing 3 (PNPLA3) rs738409 (also referred to as adiponutrin) is reported to be a major risk factor for NAFLD. 2 In addition, common genetic variations in the membrane-bound O-acyltransferase domain-containing 7 (MBOAT7) and in the transmembrane 6 superfamily member 2 (TM6SF2) genes have also been associated with increased susceptibility to NAFLD and its severity. 3 Comorbid NAFLD is becoming progressively more prevalent in certain conditions such as the metabolic syndrome, which is a wellestablished risk factor. 4 NAFLD has also been reported in up to 80%
of patients with type 2 diabetes. 5 Nondiabetic endocrinopathies are also increasingly being linked to fatty liver. 6, 7 Hypothyroidism has been associated with NAFLD, 6 as have patients with increased circulation of androgens, evidenced by occurrence rates of up to 70%
in women with polycystic ovarian syndrome (PCOS).
8
Acromegaly is another endocrinopathy of interest, which is characterized by the hypersecretion of growth hormone (GH). GH triggers hepatic and systemic insulin-like growth factor 1 (IGF-1) production. 9 Both GH and IGF-1 are suggested to play an important role in the metabolism of hepatic fat. 10 Treatment-naïve patients with acromegaly are reported to commonly have elevated serum triglyceride concentrations in addition to insulin resistance and visceral adipose tissue accumulation-factors associated with NAFLD. 11 Furthermore, certain treatments for acromegaly can compound this clinical picture, as they have been associated with altered hepatic fat accumulation and liver dysfunction. [12] [13] [14] This has been illustrated in a randomized study that reported increased accumulation of hepatic fat after cotreatment of somatostatin analogue with the GH receptor antagonist, pegvisomant.
14 Overall, there has been a little attention on the role of NAFLD in patients with acromegaly; thus, the objective of this cross-sectional study was to investigate the associations between the clinical features of acromegaly and NAFLD, taking into account the genetic make-up of the individual patients.
| PATIENTS AND ME THODS
This study recruited adult patients diagnosed with acromegaly from within the Department of Medicine II at Saarland University Medical
Center, who were willing to provide informed consent for participation. The diagnosis of acromegaly was based on IGF-1 concentrations in blood and the absence of growth hormone suppression during an oral glucose tolerance test (OGTT 
| Genotyping of risk variants
For genotyping, we followed the membrane-based QIAamp protocol (Hilden, Germany) for the DNA isolation from EDTA blood. 
| Statistical analysis
The software programs spss 20.0 (SPSS) and Graphpad prism 7.04 
| RE SULTS

| Patient characteristics
A total of 22 patients with acromegaly who were treated at our centre were included in this cross-sectional analysis. Table 1 
| Liver profiles
Endocrine markers
Testosterone (pg/mL) 2.5 ± 1.6
Free testosterone (pg/mL)
Oestradiol (pg/mL) 14.2 ± 13.8
Cortisol (µg/dL) 10.6 (1.7-41.1)
Liver markers CAP (dB/m) 276 ± 56 CAP values increase with advancing liver disease. In terms of liver function tests, one patient had elevated ALT, AST and AP activities, and three patients had increased AST levels only; finally, raised γ-GT activities were documented in six patients.
| Lipid profiles
Overall, 68.2% of the patients displayed elevated serum TG (>150 mg/dL) and 63.6% raised TC concentrations (>200 mg/dL).
LDL cholesterol was above the normal threshold of 120 mg/dL in 40.9%, and 9.0% of the patients had HDL cholesterol values <40 mg/ dL. HbA1c was above the normal range in six patients (all of which had a diagnosis of diabetes). Incidentally, not all the diabetic patients presented with hepatic steatosis.
| Endocrine markers
IGF-1 concentrations were within the normal range for 18 of the 22 patients (82%) on treatment. When comparing serum cortisol concentrations between patients, only three patients demonstrated elevated values. Prolactin concentrations were within the normal range for six patients and were elevated in one patient, whilst 15
patients had values below normal. Both STH and SHBG concentrations were raised in two and four patients, respectively, and three patients had SHBG levels below the normal threshold. Only one patient had elevated ACTH concentrations. Two patients displayed total testosterone levels above the threshold, four were below, and 10 patients were in the normal range (there were missing values for six patients).
The majority of patients had FSH values within the normal range (n = 16), and one and four patients had values above and below this range, respectively. Likewise, 13 patients had normal LH concentrations and seven displayed elevated values (cut-off could not be determined for two patients). Finally, six patients had normal oestradiol levels, whereas this was below the normal threshold for one patient (the cut-off could not be determined for 15 patients).
| Medications
The patient sample was documented as taking the following medications: seven patients were receiving octreotide only, four were on octreotide and cabergoline cotreatment, and one patient received octreotide together with pegvisomant. Two patients were taking pegvisomant alone, and one was receiving pegvisomant with cabergoline. Seven patients were untreated.
| Genotyping results
Genotyping results were available for 21 of the 22 patients and are summarized in Table 2 . Nine patients were carriers of the PNPLA3 
| Hepatic steatosis is influenced by risk genotypes in patients with acromegaly
CAP values were available for 18 of the 21 patients who were genotyped. From these, 17 were included based on fulfilling our criteria for CAP inclusion. Heterozygous carriers of the prosteatogenic (M)
PNPLA3 risk allele had significantly (P = .045) higher CAP as compared to the wild-type group (Figure 2) . A comparison of CAP values based on MBOAT7 and TM6SF2 genotypes revealed no significant differences between wild-type, heterozygous and homozygous groups and the wild-type and heterozygous groups, respectively.
Nevertheless, mean CAP values were lower in carriers of the wildtype genotype than in heterozygous patients for both genotypes, as illustrated in Figure 2 . Additionally, the MBOAT7 genotype included patients homozygous for the risk allele, in whom the mean CAP value was highest.
F I G U R E 1 A, Boxplots depicting noninvasive transient elastography results for controlled attenuation parameter (CAP)
and liver stiffness measurements (LSMs) in the entire study group. B, Boxplots comparing CAP values for the four different groups of patients with acromegaly: patients without fatty liver compared to patients with fatty liver, and with fibrosis and cirrhosis. The CAP cut-off for fatty liver was 248 dB/m. Liver fibrosis was defined by LSM > 6.0 kPa, and LSM > 12.0 kPa indicated cirrhosis 
| PNPLA3 p.I148M risk allele is associated with higher CAP
| Clinical phenotypes do not differ based on the presence of hepatic steatosis
A subgroup comparison was carried out based on the presence or absence of hepatic steatosis, as defined by CAP cut-off 248 dB/m.
This corresponded to 12 vs 6 patients; however, when comparing the clinical characteristics between these two groups, no significant differences were observed.
A further analysis comparing CAP scores in patients receiving pegvisomant with those not on medications or with those receiving somatostatin analogues or cabergoline revealed no differences.
| Univariate regression analysis reveals associations with CAP
Linear univariate regression analysis for CAP values as continuous variable was carried out for two variables (PNPLA3 genotype and BMI), agreed on a priori; however, no significant associations were observed.
| D ISCUSS I ON
This cross-sectional study evaluated the clinical features of patients with acromegaly and assessed for hepatic steatosis as well as for genetic determinants related to NAFLD. Hepatic steatosis was present in 66% of the patients when using a CAP cut-off of 248 dB/m, this finding is similar to another recent study that reported hepatic steatosis in 61% of acromegaly patients using the hepatic steatosis index. 20 Furthermore, five of the included patients with hepatic steatosis also had fibrosis and one had cirrhosis. Moreover, the PNPLA3 risk allele was highly prevalent in this small sample (in 41% of the patients F I G U R E 2 Individual patient CAP scores (as well as mean ± SD) based on genotype for the following single nucleotide polymorphisms: patatin-like phospholipase domain-containing 3 (PNPLA3) p.I48M; membrane-bound O-acyltransferase domain-containing 7 (MBOAT7) p.G17E; and transmembrane 6 superfamily member 2 (TM6SF2) p.E167K. CAP values differed significantly (P = .045) between patients who were heterozygous carriers of the PNPLA3 risk allele (IM) as compared to the wild-type patients (II). No significant differences in CAP were demonstrated between the three MBOAT7 genotypes, where the lowest mean CAP value was observed in carriers of the wild-type genotype (GG) and the highest in patients homozygous for the risk allele (EE). No difference in CAP was observed between the TM6SF2 genotypes threshold for hepatic steatosis (>248 dB/m). Moreover, the mean CAP value for these patients corresponded to advanced steatosis (S3) and was significantly higher (P = .045) when compared to the mean CAP value of the wild-type patients who did not possess the risk allele, which corresponded to mild steatosis, S1.
19
How acromegaly is associated with increased risk of hepatic steatosis is not entirely understood, but might be mediated by the presence of obesity. Moreover, we previously reported significantly
higher CAP values in carriers of the PNPLA3 risk allele in patients with chronic liver diseases. 16 Moreover, metabolic and endocrine factors may interact and have dynamic effects on hepatic steatosis in acromegaly. Specifically, growth hormone (GH) stimulates insulin resistance via its induction of gluconeogenesis and glycogenolysis, and indeed, hepatic lipid accumulation has been associated not only with GH deficiency but also with GH excess. 20 Detrimental consequences on glucose metabolism, insulin signalling and adipose tissue have been documented in patients with acromegaly and GH excess.
For instance, insulin resistance is associated with increased lipolysis and elevated circulating free fatty acids are seen in acromegaly patients. 21 On the contrary, deficiencies of both GH and IGF-1 have been associated with an increased risk of NAFLD, as shown in animal models with GH deficiency, in whom hepatic steatosis is reversed upon correction of GH and IGF-1 concentrations. 22 Indeed, lower GH concentrations have been reported in human studies with participants diagnosed with NAFLD. 23, 24 Moreover, low serum IGF-1 concentrations have also been associated with NAFLD and it has been suggested that hepatic insulin resistance modulates hepatic GH production and thus IGF-1 concentrations. 25, 26 A recent study showed hepatic steatosis (as assessed by a surrogate marker, the hepatic steatosis index) to be related to insulin resistance and the reduction of IGF-1 and GH levels; after 12 months of follow-up, improvements to insulin sensitivity paralleled reductions of hepatic steatosis. 20 The observed risk with GH and IGF-1 deficiencies would imply that treated patients with acromegaly might be prone to develop NAFLD, because treatment does, in some cases, lead to the development of GH deficiency, as illustrated in a recently published case study. 27 Moreover, an intervention study and another case study both report histological NASH resolution upon GH correction in patients with GH deficiency. 28, 29 None of the patients herein had a deficiency in IGF-1 concentrations; therefore, other mechanisms must exist through which NAFLD risk is amplified.
The GH receptor antagonist, pegvisomant, has also been associ- 
| CON CLUS ION
Patients with both acromegaly and PNPLA3 genetic risk present with a greater degree of hepatic steatosis as compared to patients with acromegaly without this genetic risk. This association should be investigated in larger patient cohorts. Since comorbid NAFLD might compound prognosis in such patients, further research into the role of NAFLD in acromegaly is warranted.
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